1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with cyproterone acetate in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (cyproterone acetate) | Trials (cyproterone acetate) | Recent Studies (post-2010) (cyproterone acetate) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 1,845 | 339 | 261 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | cyproterone acetate (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.225 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.225 | |
| Androgen receptor | Homo sapiens (human) | 0.1408 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.339 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.225 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.225 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.225 | |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.045 | |
| Mu-type opioid receptor | Homo sapiens (human) | 2.183 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armutcu, F; Carlioglu, A; Gumus, II; Karakurt, F; Kasapoglu, B; Kaygusuz, I; Keskin, EA; Koca, C; Uysal, A; Uysal, S | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cyproterone acetate
| Article | Year |
|---|---|
The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Androgen Antagonists; Aryldialkylphosphatase; Body Mass Index; Carboxylic Ester Hydrolases; Case-Control Studies; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Metformin; Phospholipase A2 Inhibitors; Platelet Activating Factor; Polycystic Ovary Syndrome; Polymorphism, Single Nucleotide; Treatment Outcome | 2014 |